MA52545B1 - Anticorps pour radionucléides chélatés - Google Patents

Anticorps pour radionucléides chélatés

Info

Publication number
MA52545B1
MA52545B1 MA52545A MA52545A MA52545B1 MA 52545 B1 MA52545 B1 MA 52545B1 MA 52545 A MA52545 A MA 52545A MA 52545 A MA52545 A MA 52545A MA 52545 B1 MA52545 B1 MA 52545B1
Authority
MA
Morocco
Prior art keywords
antibodies
chelated radionuclides
chelated
radionuclides
invention further
Prior art date
Application number
MA52545A
Other languages
English (en)
Other versions
MA52545A (fr
Inventor
Joerg Moelleken
Pablo Umana
Christian Klein
Guy Georges
Barbara Weiser
Sebastian Fenn
Alexander Haas
Florian LIPSMEIER
Felix BORMANN
Daniela MATSCHEKO
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of MA52545A publication Critical patent/MA52545A/fr
Publication of MA52545B1 publication Critical patent/MA52545B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0495—Pretargeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Detergent Compositions (AREA)

Abstract

La présente invention concerne des anticorps qui se lient spécifiquement à des radionucléides chélatés, y compris des anticorps bispécifiques. L'invention concerne en outre l'utilisation de tels anticorps bispécifiques dans des applications telles que la radioimmunoimagerie et la radioimmunothérapie. L'invention concerne en outre des agents de clarification et des compositions utiles dans de tels procédés. Les radionucléides chélatés peuvent être un chélate DOTAM-plomb (Pb).
MA52545A 2018-04-16 2019-04-16 Anticorps pour radionucléides chélatés MA52545B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658468P 2018-04-16 2018-04-16
EP19723014.7A EP3781200B1 (fr) 2018-04-16 2019-04-16 Anticorps pour radionucléides chélatés
PCT/EP2019/059856 WO2019201959A1 (fr) 2018-04-16 2019-04-16 Anticorps pour radionucléides chélatés

Publications (2)

Publication Number Publication Date
MA52545A MA52545A (fr) 2021-02-24
MA52545B1 true MA52545B1 (fr) 2024-08-30

Family

ID=66476592

Family Applications (1)

Application Number Title Priority Date Filing Date
MA52545A MA52545B1 (fr) 2018-04-16 2019-04-16 Anticorps pour radionucléides chélatés

Country Status (31)

Country Link
US (2) US20220389116A1 (fr)
EP (2) EP3781200B1 (fr)
JP (3) JP7475283B2 (fr)
KR (1) KR102884852B1 (fr)
CN (1) CN112261952A (fr)
AR (1) AR115053A1 (fr)
AU (1) AU2019254537B2 (fr)
BR (1) BR112020021061A2 (fr)
CA (1) CA3096338A1 (fr)
CL (1) CL2020002680A1 (fr)
CR (1) CR20200548A (fr)
DK (1) DK3781200T3 (fr)
ES (1) ES2985352T3 (fr)
FI (1) FI3781200T3 (fr)
HR (1) HRP20241013T1 (fr)
HU (1) HUE067622T2 (fr)
IL (1) IL277575B2 (fr)
LT (1) LT3781200T (fr)
MA (1) MA52545B1 (fr)
MX (1) MX2020010954A (fr)
MY (1) MY207044A (fr)
PE (1) PE20210442A1 (fr)
PL (1) PL3781200T3 (fr)
PT (1) PT3781200T (fr)
RS (1) RS65753B1 (fr)
SG (1) SG11202010066TA (fr)
SI (1) SI3781200T1 (fr)
TW (1) TWI874314B (fr)
UA (1) UA130541C2 (fr)
WO (1) WO2019201959A1 (fr)
ZA (1) ZA202006121B (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (fr) 2019-01-30 2020-08-06 Immutics, Inc. Anticorps anti-gal3 et leurs utilisations
AR119382A1 (es) * 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
EP4157338A4 (fr) 2020-05-26 2024-11-13 TrueBinding, Inc. Méthodes de traitement de maladies inflammatoires par blocage de la galectine-3
CR20230076A (es) * 2020-07-10 2023-03-13 Hoffmann La Roche Anticuerpos que se unen a células cancerosas y dirigen radionucleótidos a dichas células
JP2024504931A (ja) 2021-01-12 2024-02-02 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト がん細胞に結合し、放射性核種を前記細胞に標的化するスプリット抗体
CA3204291A1 (fr) 2021-01-13 2022-07-21 F. Hoffmann-La Roche Ag Polytherapie
CN116744981A (zh) * 2021-01-13 2023-09-12 豪夫迈·罗氏有限公司 组合疗法
JP2024546810A (ja) 2021-12-15 2024-12-26 ワイ－マブス セラピューティクス， インコーポレイテッド 多量体化が低減されているｓｃＦｖ及び抗体
WO2024099526A1 (fr) 2022-11-08 2024-05-16 Y-Mabs Therapeutics, Inc. Composés d'anticorps bispécifiques
WO2025176614A1 (fr) 2024-02-20 2025-08-28 F. Hoffmann-La Roche Ag Nouveaux anticorps de pré-ciblage et leurs utilisations
WO2026041568A1 (fr) 2024-08-20 2026-02-26 F. Hoffmann-La Roche Ag Anticorps se liant à cd3 et dotam
WO2026082710A1 (fr) 2024-10-16 2026-04-23 F. Hoffmann-La Roche Ag Récepteurs recombinants inductibles par de petites molécules

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201608192SA (en) * 2014-04-11 2016-10-28 Medimmune Llc Bispecific her2 antibodies
ES2809598T3 (es) 2014-12-23 2021-03-04 Inst Nat Sante Rech Med Composiciones farmacéuticas para el tratamiento de superinfecciones bacterianas post-influenza
EP3253799B1 (fr) * 2015-02-05 2020-12-02 Molecular Templates, Inc. Molécules multivalentes de liaison à cd20 comprenant des régions effectrices de sous-unité a de la toxine shiga et compositions enrichies correspondantes
CN107847584B (zh) * 2015-02-09 2022-01-25 纪念斯隆凯特琳癌症中心 具有人a33抗原和dota金属复合物亲和力的多特异性抗体及其用途
PE20180484A1 (es) * 2015-10-02 2018-03-07 Hoffmann La Roche Moleculas biespecificas de union a antigeno activadoras de celulas t
EP3243836A1 (fr) * 2016-05-11 2017-11-15 F. Hoffmann-La Roche AG Molécules de liaison à un antigène contenant un trimère d'un ligand de la famille du tnf fusionné en terminaison c
CN112638416A (zh) 2018-04-16 2021-04-09 奥兰诺医药公司 针对螯合的放射性核素的抗体和清除剂

Also Published As

Publication number Publication date
CL2020002680A1 (es) 2021-02-12
SI3781200T1 (sl) 2024-09-30
IL277575B2 (en) 2025-11-01
EP3781200B1 (fr) 2024-05-29
ZA202006121B (en) 2025-05-28
JP2024056687A (ja) 2024-04-23
PE20210442A1 (es) 2021-03-08
EP3781200A1 (fr) 2021-02-24
TW202011987A (zh) 2020-04-01
JP2026062683A (ja) 2026-04-10
HRP20241013T1 (hr) 2024-10-25
IL277575A (en) 2020-11-30
MA52545A (fr) 2021-02-24
HUE067622T2 (hu) 2024-10-28
CA3096338A1 (fr) 2019-10-24
CR20200548A (es) 2021-01-20
JP2021520832A (ja) 2021-08-26
IL277575B1 (en) 2025-07-01
JP7475283B2 (ja) 2024-04-26
PT3781200T (pt) 2024-07-19
UA130541C2 (uk) 2026-03-18
SG11202010066TA (en) 2020-11-27
BR112020021061A2 (pt) 2021-02-17
CN112261952A (zh) 2021-01-22
US20220389116A1 (en) 2022-12-08
ES2985352T3 (es) 2024-11-05
MY207044A (en) 2025-01-27
TWI874314B (zh) 2025-03-01
AU2019254537A1 (en) 2020-10-29
AR115053A1 (es) 2020-11-25
FI3781200T3 (fi) 2024-07-31
EP4406607A3 (fr) 2024-10-16
DK3781200T3 (da) 2024-08-05
AU2019254537B2 (en) 2025-06-19
WO2019201959A1 (fr) 2019-10-24
KR102884852B1 (ko) 2025-11-14
US20260015436A1 (en) 2026-01-15
KR20210005885A (ko) 2021-01-15
PL3781200T3 (pl) 2024-09-16
RS65753B1 (sr) 2024-08-30
EP4406607A2 (fr) 2024-07-31
LT3781200T (lt) 2024-08-12
MX2020010954A (es) 2020-11-09

Similar Documents

Publication Publication Date Title
MA52545B1 (fr) Anticorps pour radionucléides chélatés
MA46708B1 (fr) Anticorps anti-pd1 et leurs utilisations
MA29243B1 (fr) Agonistes de pyy et leurs utilisations
MA58293B1 (fr) Molécules de liaison pd-1 et leurs procédés d'utilisation
MA52773B1 (fr) Anticorps anti-cd3 et leurs utilisations
MA39313A1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
MA30047B1 (fr) Procede destine a traiter une lesion articulaire
MA34753B1 (fr) Compositions et procédés de traitement dans des applications cliniques à large spectre, indifférenciées ou mixtes
MA30345B1 (fr) Formulation d'anticorps monoclonal humain anti-igf-1r
CY1110337T1 (el) Παρασκευη πρεγκαμπαλινης και σχετικων ενωσεων
MA30470B1 (fr) Compositions pharmaceutiques d'anticorps anti-cd40 antagoniste.
MA30922B1 (fr) Anticorps d'agonistes de trkb et leurs utilisations
MA52492B1 (fr) Composés inhibiteurs de rip1, procédés de préparation et d'utilisation associés
MA31605B1 (fr) Anticorps anti-cd79b humanisés, immunoconjugués, et procédés d'utilisation
MA42439B1 (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA39909B1 (fr) Conjugué anticorps de l'igf-1r-médicament et son utilisation pour le traitement du cancer
MA35740B1 (fr) Compositions et procédés pour des anticorps ciblant le facteur p
MA44909A (fr) Association thérapeutique d'un inhibiteur du cd19 et d'un inhibiteur de la btk
MA30159B1 (fr) Agents de durcissement pour composes a fonctions epoxy
PL1886140T3 (pl) Testy immunologiczne i przeciwciała wobec hormonu anty-Müllerowskiego
MA37317B1 (fr) Formulation d'anticorps il-17
MA30889B1 (fr) Inhibiteurs de la kinase mapk/erk
EP4162054A4 (fr) Compositions et procédés pour l'édition de l'épigénome
MA38342A1 (fr) Composition de revêtement durcissable oxydativement
EA200401210A1 (ru) Андрогенная фармацевтическая композиция и способ для лечения депрессии